Holen Sie sich die Stockscreener-App
15.39
1.75%
0.26
Schlusskurs vom Vortag:
$15.13
Offen:
$15.13
24-Stunden-Volumen:
803.87K
Relative Volume:
0.12
Marktkapitalisierung:
$10.51B
Einnahmen:
$125.68M
Nettoeinkommen (Verlust:
$4.81B
KGV:
2.7239
EPS:
5.65
Netto-Cashflow:
$-781.21M
1W Leistung:
+4.73%
1M Leistung:
+29.04%
6M Leistung:
+56.29%
1J Leistung:
+35.40%
1-Tages-Spanne:
$15.11
$15.48
1-Wochen-Bereich:
$14.59
$15.48
52-Wochen-Spanne:
$8.73
$16.05
Roivant Sciences Ltd Stock (ROIV) Company Profile
Firmenname
Roivant Sciences Ltd
Sektor
Branche
Telefon
441-295-5950
Adresse
7TH FLOOR, 50 BROADWAY, LONDON
Vergleichen Sie ROIV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
15.39 | 10.33B | 125.68M | 4.81B | -781.21M | 5.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
403.00 | 100.41B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.96 | 59.59B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.43 | 59.77B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
768.45 | 45.14B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
343.93 | 37.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-02 | Eingeleitet | Citigroup | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Buy |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-01-05 | Eingeleitet | Piper Sandler | Overweight |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-17 | Eingeleitet | Guggenheim | Buy |
| 2023-06-08 | Eingeleitet | BofA Securities | Neutral |
| 2022-10-27 | Eingeleitet | JP Morgan | Overweight |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-12-15 | Eingeleitet | Goldman | Buy |
| 2021-11-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-28 | Eingeleitet | Citigroup | Buy |
| 2021-10-26 | Eingeleitet | Cowen | Outperform |
| 2021-10-26 | Eingeleitet | Jefferies | Buy |
| 2021-10-26 | Eingeleitet | Truist | Buy |
Alle ansehen
Roivant Sciences Ltd Aktie (ROIV) Neueste Nachrichten
Can Roivant Sciences Ltd. (87S) stock double in coming yearsWeekly Trend Summary & Verified Momentum Stock Ideas - newser.com
Will Roivant Sciences Ltd. continue its uptrendEarnings Recap Report & Fast Moving Stock Watchlists - newser.com
Roivant Sciences stock poised for growth, Goldman Sachs reiterates Buy By Investing.com - Investing.com South Africa
Roivant Sciences stock poised for growth, Goldman Sachs reiterates Buy - Investing.com India
Roivant Sciences Ltd.’s volatility index tracking explainedGap Up & Growth Focused Stock Reports - newser.com
Is Roivant Sciences Ltd. (87S) stock undervalued historicallyMarket Activity Summary & AI Driven Stock Price Forecasts - newser.com
Why retail investors pile into Roivant Sciences Ltd. stockBond Market & Real-Time Stock Price Movement Reports - newser.com
Why Roivant Sciences Ltd. (87S) stock attracts wealthy investorsOil Prices & Accurate Technical Buy Alerts - newser.com
What sentiment indicators say about Roivant Sciences Ltd. stockProfit Target & Risk Controlled Stock Alerts - newser.com
Long term hold vs stop loss in Roivant Sciences Ltd.Trade Analysis Report & Long-Term Safe Investment Plans - newser.com
Is Roivant Sciences Ltd. (87S) stock worth holding before Fed meeting - newser.com
LVW Advisors LLC Makes New $199,000 Investment in Roivant Sciences Ltd. $ROIV - MarketBeat
Will Roivant Sciences Ltd. (87S) stock outperform value peersFed Meeting & Capital Protection Trading Alerts - newser.com
Can Roivant Sciences Ltd. stock deliver consistent earnings growth2025 Price Action Summary & Expert Curated Trade Ideas - newser.com
What analysts say about Roivant Sciences Ltd stockDividend Stability Analysis & Fast Growing Investment Ideas - earlytimes.in
How Investors May Respond To Roivant Sciences (ROIV) Positive Phase 3 Results for Brepocitinib in Dermatomyositis - simplywall.st
Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Is Roivant Sciences Ltd a good long term investmentVolatility Index Analysis & These Stocks Are Just Getting Started - Early Times
Transcript : Roivant Sciences Ltd. Presents at Bernstein 2nd Annual Global Healthcare Conference, Sep-23-2025 01 - MarketScreener
Transcript : Roivant Sciences Ltd. Presents at Bank of America Global Healthcare Conference 2025, Sep-24-2025 09 - MarketScreener
Roivant Sciences president Venker sells $25.5m in shares By Investing.com - ng.investing.com
Roivant Sciences at Bank of America Global Healthcare: Strategic Insights By Investing.com - Investing.com Australia
analysts-double-sales-forecasts-for-roivant-s-brepocitinib-after-trial-success-93143405 - S&P Global
Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 611,000 Shares - MarketBeat
Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 416,182 Shares - MarketBeat
Roivant Sciences president Venker sells $25.5m in shares - Investing.com
Are You Looking for a Top Momentum Pick? Why Roivant Sciences Ltd. (ROIV) is a Great Choice - Yahoo Finance
Roivant Sciences (NASDAQ:ROIV) Given New $22.00 Price Target at Leerink Partners - MarketBeat
Inspire Investing LLC Invests $303,000 in Roivant Sciences Ltd. $ROIV - MarketBeat
The Goldman Sachs Group Boosts Roivant Sciences (NASDAQ:ROIV) Price Target to $24.00 - MarketBeat
Roivant Sciences (NASDAQ:ROIV) Price Target Raised to $20.00 at HC Wainwright - MarketBeat
Bank of America Forecasts Strong Price Appreciation for Roivant Sciences (NASDAQ:ROIV) Stock - MarketBeat
Roivant Sciences (NASDAQ:ROIV) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
Guggenheim Boosts Roivant Sciences (NASDAQ:ROIV) Price Target to $21.00 - MarketBeat
Ramaswamy-backed Strive to buy Semler in $1.3 billion deal all stock deal, boosting Bitcoin holdings - Reuters
What is HC Wainwright's Forecast for ROIV Q1 Earnings? - MarketBeat
Leerink Partnrs Has Bullish Estimate for ROIV Q2 Earnings - MarketBeat
Roivant Sciences (NASDAQ:ROIV) Hits New 1-Year HighWhat's Next? - MarketBeat
Roivant Sciences Hits Day High with Strong 7.76% Intraday Surge - Markets Mojo
Roivant Sciences (NASDAQ:ROIV) CEO Matthew Gline Purchases 3,315 Shares - MarketBeat
Roivant Sciences (ROIV): Assessing Valuation After Positive Phase 3 Brepocitinib Results in Dermatomyositis Trial - simplywall.st
History Review: Will Roivant Sciences Ltd benefit from rate cutsOptions Play & Weekly Watchlist for Hot Stocks - خودرو بانک
Finanzdaten der Roivant Sciences Ltd-Aktie (ROIV)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):